Acute Agitation and Aggression Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Acute Agitation and Aggression Treatment Market is segmented by Route of Administration (Oral, Intramuscular, Others), Drug Class (Anti-psychotics, Benzodiazepines, Others), End Users (Hospitals & Ambulatory Surgical Centers. Psychiatric Care Facilities, Others), and Geography.

Market Snapshot

AAAT_Image 1
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.9 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Global Acute Agitation and Aggression Treatment market is expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include rise in burden of mental illness and increase in agitation in patients, increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017, to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.

Scope of the Report

Agitation are generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The scope of the market studied includes the drugs which acutely agitated patients are offered.

By Route of Administration
By Drug Class
By End Users
Hospitals & Ambulatory Surgical Centers
Psychiatric Care Facilities
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Anti-psychotics is Expected to Hold Significant Market Share in the Drug Class Segment

The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting. 

Moreover, robust development pipeline coupled with the activity of the manufacturers in launch and collaborations projected to boost the segment growth. For Instance, in May 2017, Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer’s-type dementia. Furthermore, the growing burden of risk factors fr agitation and aggression such as neurological disorders projected to bolster the market growth over the forecast period.


North America Dominates the Market and Expected to do Same in the Forecast Period

As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer’s Association, 2018). All these factors are expected to drive the market growth in the region.

Acute Agitation and Aggression Treatment Market - Growth Rate by Region image

Competitive Landscape

The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Geriatric Population and Increase in Agitation in Patients

      2. 4.2.2 Increase in Focus on Creating Awareness About Agitation and Aggression

      3. 4.2.3 Ongoing Research on the Development of Novel Treatment for Agitation

    3. 4.3 Market Restraints

      1. 4.3.1 Preference for Non-Pharmacological Interventions

      2. 4.3.2 Social Stigma Associated With Mental Illness

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Route of Administration

      1. 5.1.1 Oral

      2. 5.1.2 Intramuscular

      3. 5.1.3 Others

    2. 5.2 By Drug Class

      1. 5.2.1 Anti-psychotics

      2. 5.2.2 Benzodiazepines

      3. 5.2.3 Others

    3. 5.3 By End Users

      1. 5.3.1 Hospitals & Ambulatory Surgical Centers

      2. 5.3.2 Psychiatric Care Facilities

      3. 5.3.3 Others

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Eli Lilly and Company

      2. 6.1.2 Pfizer, Inc.

      3. 6.1.3 Otsuka Holdings

      4. 6.1.4 GlaxoSmithKline

      5. 6.1.5 H. Lundbeck A/S

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Bristol-Myers Squibb

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Acute Agitation and Aggression Treatment Market market is studied from 2018 - 2026.

The Acute Agitation and Aggression Treatment Market is growing at a CAGR of 4.9% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Eli Lilly and Company, Pfizer, Inc. are the major companies operating in Acute Agitation and Aggression Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!